Cabozantinib is a multi-kinase inhibitor indicated for the treatment of RCC (Renal Cell Carcinoma) and HCC (Hepatocellular Carcinoma). It blocks VEGFR, MET, and a bunch of other kinases. The tablets come in 20, 40, and 60 mg doses, all with that film coating.
For adults, you’re looking at 60 mg once a day, on an empty stomach. Each bottle packs 30 tablets. The idea here is to help patients live longer, have better responses, and keep the cancer at bay.
